Navigation Links
Risk of abnormally slow heart rate twice as high in those taking drugs to slow Alzheimer's
Date:10/1/2009

TORONTO, Ont., October 1, 2009 People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.

Researchers from St. Michael's Hospital and Ontario's Institute for Clinical Evaluative Sciences (ICES) analyzed data from 1.4 million people aged 67 and older to see whether the risk for bradycardia was higher for those taking drugs called cholinesterase inhibitors.

Bradycardia is defined as an abnormally slow resting heart rate (under 60 beats per minute). Although it can be asymptomatic, it can also cause fainting, palpitations, shortness of breath, or even death.

"We wanted to see if there was a link between initiation of a cholinesterase inhibitor and subsequent hospitalization for bradycardia," explains lead author Laura Y. Park-Wyllie, a researcher at St. Michael's Hospital .

The three cholinesterase-inhibiting drugs currently approved for use in Canada are donepezil (brand name Aricept); rivastigmine (marketed as Exelon and Exelon Patch); and galantamine (branded Reminyl).

Most of the patients whose records were analyzed for the study had been prescribed donepezil.

The results of the study showed that older patients hospitalized with bradycardia were more than twice as likely to have recently started on a cholinesterase inhibitor such as donepezil for Alzheimer's disease compared to those without bradycardia.

The findings appear in the September 2009 issue of PLoS Medicine, an open-access online medical journal.

The researchers say that as the prevalence of Alzheimer's disease and other forms of dementia increases, more people aged 65 years and older will be treated with a cholinesterase inhibitor.

"It will be increasingly more important to prescribe these drugs judiciously as they carry a risk of serious adverse events," Park-Wyllie says. "A careful clinical evaluation is required before and after initiating these drugs, and they should only be continued when there is a definite positive response."

The potential cardiovascular toxicity of these dementia drugs may be underappreciated by clinicians, Park-Wyllie adds. More than half of the patients who had been hospitalized with bradycardia resumed taking their cholinesterase inhibitor after being discharged.

"Our study provides evidence of the potential adverse effect of cholinesterase inhibitors on heart rate. Health professionals need to reassess the merits of continued therapy in patients who develop bradycardia while taking these drugs," she says.

About cholinesterase inhibitors and dementia

Cholinesterase inhibitors are commonly prescribed to delay the progression of symptoms such as confusion and long-term memory loss in people with mild to moderate Alzheimer's disease.

It's known that people with dementia tend to have lower levels of a brain chemical called acetylcholine; the drugs work by boosting these levels. Reported side effectsincluding diarrhea, muscle cramps and abnormally slow heartbeatmay be related to increasing levels of acetylcholine in the body.

The benefits of cholinesterase inhibitors for people with Alzheimer's disease are generally small. The drugs do not reverse the effects of dementia. Other research suggests that in about half of patients, the drugs delay the worsening of symptoms for between six months to a year, although a minority of patients may benefit more.


'/>"/>

Contact: Julie Saccone
sacconej@smh.toronto.on.ca
416-864-5047
St. Michael's Hospital
Source:Eurekalert

Related medicine news :

1. Endometrial Ablation Offers Relief for Abnormally Heavy or Irregular Menstrual Bleeding
2. Pre-Birth Exposure to 1918 Flu Raised Heart Risks, Study Finds
3. Heart-Pacing Devices Hold Promise for Heart Failure
4. Cardiac stem cell trial seeks to treat some heart attack patients
5. Heartland Information Services Appoints New Chief Executive Officer
6. Study Finds Fish Wont Prevent Heart Failure
7. Despite size, NFL players not more likely to develop heart disease, even after retirement
8. No major role for fish in the prevention of heart failure
9. Study offers less complex, minimally invasive procedure to treat heart valve leak
10. Fetal Surgery May Treat Heart Defect
11. Heart Patients Benefit From At-Home Care, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: